Protocol development in integrative medicine is not typically a simple process. Individuals require individualized care, and what works for one patient may not work for another.

To establish these protocols, we first developed a Rating Scale that could be used to discern the rigor of evidence supporting a specific nutrient’s therapeutic effect.

The following protocols were developed using only -quality evidence.

Qualifying studies
Minimum requirements

Dysfunctional gastrointestinal processes vary widely. Chronic abdominal pain with persistent or recurrent tendencies may be associated with abnormalities in bowel function and structure. The prevalence of gastrointestinal problems presenting in this way ranges anywhere from 5 to 20% of people being affected. (Ford and Vandvik, 2012)

Depending on the symptoms presented, there are a variety of ways to help ameliorate symptoms. For example, antispasmodics such as peppermint oil can help with pain associated with digestive dysfunction. (Merat et al., 2012) Probiotics, human milk oligosaccharides, and fiber contribute to improving stool consistency by creating a healthy microbiota, which can lend to easier passing and serve as an indicator of digestive health. (Iribarren et al., 2020)(Liang et al., 2019)(Palsson et al., 2020)(Yasukawa et al., 2019)

Based on current research findings, the ingredients in the protocol below have demonstrated efficacy in improving a variety of factors associated with gastrointestinal upset or digestive dysfunction.

Peppermint oil

180 mg, 3 times/day, minimum 4 weeks (Cash et al., 2016); other dosages may vary

  • 42.4% of patients with irritable bowel syndrome (IBS) were pain free after 8 weeks of supplementation with delayed-release peppermint oil compared to 22.2% in placebo. The proportion of patients reporting persistent pain decreased from 42% to 15% in the peppermint oil group, whereas it increased from 33% to 52% in the placebo group. (Merat et al., 2010)
  • Peppermint oil supplementation ameliorated symptoms of IBS at 24 hours, shown by a decrease in Total IBS Symptom Score (TISS) of 19.6%, compared to 10.3% in the placebo group. After 4 weeks, the decrease in TISS scores was 40% in the treatment group compared to 24.3% in the placebo group. (Cash et al., 2016)
  • 75% of patients treated with enteric-coated peppermint oil capsules for 4 weeks experienced at least a 50% reduction in TISS scores compared to 38% in the placebo group. (Cappello et al., 2007)
Peppermint oil in the Fullscript catalog

Soluble dietary fiber

Ranges widely, from 4.1–40 per day for 3–16 weeks as per this systematic review (Nagarajan et al., 2015)

  • A systematic review of 22 studies with dose ranging 4.1–40 g per day for 3–16 weeks determined that soluble (but not insoluble) fiber supplementation resulted in a significant improvement in global assessment of symptoms (RR 1.49) as well as abdominal pain scores. (Nagarajan et al., 2015)
  • In patients with a tendency toward diarrhea (IBS-D), 5 g per day of partially hydrolyzed guar gum soluble fiber improved and normalized bristol stool scale ratings after 3 months compared to placebo. (Yasukawa et al., 2019)
  • After 12 weeks, symptom severity improved by 90 points in the psyllium group (10 g per day) (RR 1.60) compared to 29 points in the placebo and 58 points in bran groups in patients with IBS aged 18–65. The group receiving bran had a high dropout rate due to symptoms of IBS worsening. (Bijkerk et al., 2009)
  • A systematic review of 14 studies involving 906 patients found that soluble fiber (but not insoluble fiber) significantly improved IBS symptoms (RR 0.86). (Moayyedi et al., 2014)
Fiber in the Fullscript catalog


50 billion CFU, twice per day, minimum 12 weeks, (Preston et al., 2019) or 25–50 billion CFU, 1–3 times per day, as per this systematic review (Didari et al., 2015

  • A systematic review of 15 studies with 1,793 patients found that probiotics reduced pain and symptom severity scores in patients with IBS. Relative risk (RR) of general symptom improvement for 7 of the key trials was 2.14, in favor of probiotics over placebo. (Didari et al., 2015)
  • Another systematic review of 43 RCTs found that probiotics reduced the risk of persistent symptoms compared to placebo (RR 0.79). Benefits were seen among global IBS, abdominal pain, bloating, and flatulence scores. (Ford et al., 2014)
  • A recent systematic review showed that 7 of 11 of the included studies reported improved IBS symptoms from probiotic supplementation compared to placebo. Multi-strain probiotics with an intervention of 8 weeks or more were more likely to have a benefit. (Dale et al., 2019)
  • Female patients with IBS-D (diarrhea-predominant IBS) and IBS-C (constipation-predominant IBS) experienced improvements in quality of life and stool frequency and consistency when supplemented with 2 capsules per day for 12 weeks of probiotics containing 50×10^9 CFU of live organisms of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2. (Preston et al., 2019)
Probiotics in the Fullscript catalog


1,200 mg 1 hour before eating, as needed (Hu et al., 2011)(Wu et al., 2008)

  • Patients with mild-to-moderate ulcerative colitis experienced a decreased severity of disease activity as well as an improvement in quality-of-life scores after 12 weeks of supplementation at 2,000 mg per day compared to placebo. Malondialdehyde levels (but not total antioxidant capacity) also decreased at both 6 and 12 weeks. (Nikkhah-Bodaghi et al., 2019
  • Two RCTs noted improved digestion, as shown by a faster gastric half-emptying time and increased antral contractions in the treatment group (1,200 mg per day ginger capsule) compared to placebo. (Hu et al., 2011)(Wu et al., 2008
  • Patients with a history of motion sickness experienced a delayed onset of nausea after vection cessation and a decrease in tachygastria activity and vasopressin release. (Lien et al., 2003
Ginger in the Fullscript catalog

Human milk oligosaccharides (HMOs) 

Only available in the U.S.

5–20 g per day, for a minimum of 4 weeks (Elison et al., 2016)(Iribarren et al., 2020)(Palsson et al., 2020)

  • Supplementing with 5 g of HMOs (4:1 mix of 2′-Fucosyllactose (2′-FL) and Lacto-N-neotetraose (LNnT)) for 12 weeks significantly improved the total percentage of bowel movements with abnormal stool consistency, overall IBS Symptom Severity Score, and quality of life. Symptoms improved the most in the first 4 weeks of supplementation. (Palsson et al., 2020)
  • Compared to placebo and 5 g of HMOs, supplementing with 10 g of 2’FL/LNnT modulated the gut microbiota of patients with IBS towards a healthier profile by increasing the population of the beneficial Bifidobacterium species in the gut without aggravating their IBS symptoms. (Iribarren et al., 2020)
  • The one-time consumption of 12 g of 2′-FL was found to increase plasma butyrate in lean men and men with prediabetes and obesity the following day. (Canfora et al., 2023)
  • A double-blind, randomized, placebo-controlled study involving 100 healthy adults found that supplementation with 2’FL and LNnT at daily doses up to 20 g for 2 weeks was safe and well tolerated. Additionally, rRNA sequencing showed HMO supplementation increased the levels of the beneficial organisms Actinobacteria and Bifidobacterium and reduced the level of the pathogenic organisms Firmicutes and Proteobacteria. (Elison et al., 2016)


The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

View template in-app
  1. Bijkerk, C. J., de Wit, N. J., Muris, J. W. M., Whorwell, P. J., Knottnerus, J. A., & Hoes, A. W. (2009). Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. <em>BMJ , 339</em>, b3154. (B)
  2. Canfora, E. E., Vliex, L. M. M., Wang, T., Nauta, A., Bouwman, F. G., Holst, J. J., Venema, K., Zoetendal, E. G., & Blaak, E. E. (2023). 2’-fucosyllactose alone or combined with resistant starch increases circulating short-chain fatty acids in lean men and men with prediabetes and obesity. Frontiers in Nutrition, 10, 1200645. (C)
  3. Cappello, G., Spezzaferro, M., Grossi, L., Manzoli, L., & Marzio, L. (2007). Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. <em>Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 39</em>(6), 530–536. (B)
  4. Cash, B. D., Epstein, M. S., & Shah, S. M. (2016). A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms. <em>Digestive Diseases and Sciences, 61</em>(2), 560–571. (B)
  5. Dale, H. F., Rasmussen, S. H., Asiller, Ö. Ö., & Lied, G. A. (2019). Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. <em>Nutrients, 11</em>(9). (A)
  6. Didari, T., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2015). Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. <em>World Journal of Gastroenterology: WJG, 21</em>(10), 3072–3084. (A)
  7. Elison, E., Vigsnaes, L. K., Rindom Krogsgaard, L., Rasmussen, J., Sørensen, N., McConnell, B., Hennet, T., Sommer, M. O. A., & Bytzer, P. (2016). Oral supplementation of healthy adults with 2’-O-fucosyllactose and lacto-N-neotetraose is well tolerated and shifts the intestinal microbiota. The British Journal of Nutrition, 116(8), 1356–1368. (B)
  8. Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014). Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. <em>The American Journal of Gastroenterology, 109</em>(10), 1547–1561; quiz 1546, 1562. (A)
  9. Ford, A. C., & Vandvik, P. O. (2012). Irritable bowel syndrome. <em>BMJ Clinical Evidence, 2012</em>. (A)
  10. Hu, M.-L., Rayner, C. K., Wu, K.-L., Chuah, S.-K., Tai, W.-C., Chou, Y.-P., Chiu, Y.-C., Chiu, K.-W., & Hu, T.-H. (2011). Effect of ginger on gastric motility and symptoms of functional dyspepsia. <em>World Journal of Gastroenterology: WJG, 17</em>(1), 105–110. (C)
  11. Iribarren, C., Törnblom, H., Aziz, I., Magnusson, M. K., Sundin, J., Vigsnaes, L. K., Amundsen, I. D., McConnell, B., Seitzberg, D., Öhman, L., & Simrén, M. (2020). Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. Neurogastroenterology and Motility: The Official Journal of the European Gastrointestinal Motility Society, 32(10), e13920. (B)
  12. Liang, D., Longgui, N., & Guoqiang, X. (2019). Efficacy of different probiotic protocols in irritable bowel syndrome: A network meta-analysis. <em>Medicine, 98</em>(27), e16068. (A)
  13. Lien, H.-C., Sun, W. M., Chen, Y.-H., Kim, H., Hasler, W., & Owyang, C. (2003). Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. <em>American Journal of Physiology. Gastrointestinal and Liver Physiology, 284</em>(3), G481–G489. (C)
  14. Merat, S., Khalili, S., Mostajabi, P., Ghorbani, A., Ansari, R., & Malekzadeh, R. (2010). The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. <em>Digestive Diseases and Sciences, 55</em>(5), 1385–1390. (B)
  15. Nagarajan, N., Morden, A., Bischof, D., King, E. A., Kosztowski, M., Wick, E. C., & Stein, E. M. (2015). The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. <em>European Journal of Gastroenterology & Hepatology, 27</em>(9), 1002–1010. (A)
  16. Nikkhah-Bodaghi, M., Maleki, I., Agah, S., & Hekmatdoost, A. (2019). Zingiber officinale and oxidative stress in patients with ulcerative colitis: A randomized, placebo-controlled, clinical trial. <em>Complementary Therapies in Medicine, 43</em>, 1–6. (C)
  17. Palsson, O. S., Peery, A., Seitzberg, D., Amundsen, I. D., McConnell, B., & Simrén, M. (2020). Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial. Clinical and Translational Gastroenterology, 11(12), e00276. (C)
  18. Preston, K., Krumian, R., Hattner, J., de Montigny, D., Stewart, M., & Gaddam, S. (2018). Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. <em>Beneficial Microbes, 9</em>(5), 697–706. (B)
  19. Wu, K.-L., Rayner, C. K., Chuah, S.-K., Changchien, C.-S., Lu, S.-N., Chiu, Y.-C., Chiu, K.-W., & Lee, C.-M. (2008). Effects of ginger on gastric emptying and motility in healthy humans. <em>European Journal of Gastroenterology & Hepatology, 20</em>(5), 436–440. (B)
  20. Yasukawa, Z., Inoue, R., Ozeki, M., Okubo, T., Takagi, T., Honda, A., & Naito, Y. (2019). Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial. <em>Nutrients, 11</em>(9). (C)
  21. Yasukawa, Z., Inoue, R., Ozeki, M., Okubo, T., Takagi, T., Honda, A., & Naito, Y. (2019). Effect of Repeated Consumption of Partially Hydrolyzed Guar Gum on Fecal Characteristics and Gut Microbiota: A Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Clinical Trial. <em>Nutrients, 11</em>(9). (C)